Roivant Sciences Ltd.
Market Cap
$20.42B
P/E Ratio
-24.38
EPS
$-1.17
Dividend Yield
0.00%
52-Week Range
$10.58 — $30.33
Volume
5.56M
Avg Volume
6.12M
Beta
1.21
Get alerted when ROIV hits your target price.
Free — enter your email to get started
P/E (TTM)
-24.38
Forward P/E
—
PEG Ratio
0.23
P/S (TTM)
1565.83
P/B (TTM)
4.75
P/FCF
-53.24
EV/EBITDA
-57.96x
EV/Sales
—
ROE (TTM)
-0.18%
ROA (TTM)
-0.15%
ROIC
-0.06%
Gross Margin
0.91%
Operating Margin
-91.31%
Net Margin
-72.26%
Debt/Equity
0.05
Current Ratio
30.66
EPS Growth (YoY)
+0.47%
Revenue Growth (YoY)
-0.62%
EPS Growth (3Y)
+1.25%
EPS Growth (5Y)
+0.40%
Sales Growth (3Y)
-0.16%
Sales Growth (5Y)
+0.04%
EPS Est (This Year)
$-1.09
EPS Est (Next Year)
$-1.20
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$6.50
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $31.25(9.5% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
-4016793
Outstanding Shares
715.70M
Float
487.29M
Free Float %
68.08%
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
NASDAQ
IPO Date
2020-12-08
Employees
908
CEO
Matthew Gline
Index Membership
—
Website
https://roivant.com
Roivant Sciences Ltd. (ROIV) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $20.42B, a P/E ratio of -24.38, ROIV is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ROIV against other stocks using dozens of fundamental and technical filters.
Roivant Sciences Ltd. (ROIV) has a trailing twelve-month (TTM) P/E ratio of -24.38. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Roivant Sciences Ltd. (ROIV) has a market capitalization of $20.42 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Roivant Sciences Ltd. (ROIV) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $31.25 implies 9.5% upside from the current price.